Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Evert

Showing results (181-190 of 228) with videos related to

Pageof 23
Sort By:
Gastroenterology|June 13, 2012
Hepatoma cells from mice deficient in glycine N-methyltransferase have increased RAS signaling and activation of liver kinase B1Nuria Martínez-López, Juan L García-Rodríguez, Marta Varela-Rey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2018
Combined CDK4/6 and Pan-mTOR Inhibition Is Synergistic Against Intrahepatic CholangiocarcinomaXinhua Song, Xianqiong Liu, Haichuan Wang, et al.
Journal of Experimental & Clinical Cancer Research : CR|September 6, 2024
HSF1 is a prognostic determinant and therapeutic target in intrahepatic cholangiocarcinomaAntonio Cigliano, Isabella Gigante, Marina Serra, et al.
Gut|September 12, 2021
Histone H3K27 demethylase KDM6A is an epigenetic gatekeeper of mTORC1 signalling in cancerSteffie Revia, Agnieszka Seretny, Lena Wendler, et al.
Genes, Chromosomes & Cancer|April 23, 2020
NTRK testing: First results of the QuiP-EQA scheme and a comprehensive map of NTRK fusion variants and their diagnostic coverage by targeted RNA-based NGS assaysMartina Kirchner, Julia Glade, Ulrich Lehmann, et al.
Journal of Experimental & Clinical Cancer Research : CR|June 2, 2022
The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human diseaseAntonio Cigliano, Shanshan Zhang, Silvia Ribback, et al.
Journal of Experimental & Clinical Cancer Research : CR|May 16, 2023
Correction: The Hippo pathway efector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human diseaseAntonio Cigliano, Shanshan Zhang, Silvia Ribback, et al.
Gastroenterology|February 20, 2013
Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinomaDarjus Felix Tschaharganeh, Xin Chen, Philipp Latzko, et al.
Cancer Research|September 12, 2025
Inhibition of GSK3 and TSC2 Mediates the Oncogenic Activity of AKT in Hepatocellular CarcinomaGuofei Cui, Yi Zhou, Weiting Liao, et al.
Genes, Chromosomes & Cancer|October 26, 2019
Testing NTRK testing: Wet-lab and in silico comparison of RNA-based targeted sequencing assaysNicole Pfarr, Martina Kirchner, Ulrich Lehmann, et al.
Pageof 23

Showing results (181-190 of 228) with videos related to

Sort By:
Pageof 23
Gastroenterology|June 13, 2012
Hepatoma cells from mice deficient in glycine N-methyltransferase have increased RAS signaling and activation of liver kinase B1Nuria Martínez-López, Juan L García-Rodríguez, Marta Varela-Rey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2018
Combined CDK4/6 and Pan-mTOR Inhibition Is Synergistic Against Intrahepatic CholangiocarcinomaXinhua Song, Xianqiong Liu, Haichuan Wang, et al.
Journal of Experimental & Clinical Cancer Research : CR|September 6, 2024
HSF1 is a prognostic determinant and therapeutic target in intrahepatic cholangiocarcinomaAntonio Cigliano, Isabella Gigante, Marina Serra, et al.
Gut|September 12, 2021
Histone H3K27 demethylase KDM6A is an epigenetic gatekeeper of mTORC1 signalling in cancerSteffie Revia, Agnieszka Seretny, Lena Wendler, et al.
Genes, Chromosomes & Cancer|April 23, 2020
NTRK testing: First results of the QuiP-EQA scheme and a comprehensive map of NTRK fusion variants and their diagnostic coverage by targeted RNA-based NGS assaysMartina Kirchner, Julia Glade, Ulrich Lehmann, et al.
Journal of Experimental & Clinical Cancer Research : CR|June 2, 2022
The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human diseaseAntonio Cigliano, Shanshan Zhang, Silvia Ribback, et al.
Journal of Experimental & Clinical Cancer Research : CR|May 16, 2023
Correction: The Hippo pathway efector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human diseaseAntonio Cigliano, Shanshan Zhang, Silvia Ribback, et al.
Gastroenterology|February 20, 2013
Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinomaDarjus Felix Tschaharganeh, Xin Chen, Philipp Latzko, et al.
Cancer Research|September 12, 2025
Inhibition of GSK3 and TSC2 Mediates the Oncogenic Activity of AKT in Hepatocellular CarcinomaGuofei Cui, Yi Zhou, Weiting Liao, et al.
Genes, Chromosomes & Cancer|October 26, 2019
Testing NTRK testing: Wet-lab and in silico comparison of RNA-based targeted sequencing assaysNicole Pfarr, Martina Kirchner, Ulrich Lehmann, et al.
Pageof 23